EBSEmergent BioSolutions Inc.

$433M

Q1 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$118M+0.8% YoY

Gross Profit

$34M29.2% margin

Operating Income

-$10M-8.1% margin

Net Income

-$5M-4.2% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

-39.2%

Cash Flow

Operating Cash Flow

-$991,000

Free Cash Flow

-$13M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$187M

Stockholders' Equity

$881M

Cash & Equivalents

$164M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$118M	$117M	+0.8%
Gross Profit	$34M	$50M	-31.8%
Operating Income	-$10M	$15M	-163.7%
Net Income	-$5M	$10M	-146.7%

EBS Q1 2018 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena